SINGAPORE, Aug. 9, 2024 /PRNewswire/ — The AI toy startup Haivivi has launched BubblePal, a groundbreaking interactive toy powered by AIGC technology—the first of its kind worldwide. This innovative product harnesses advanced AI large language model(LLM) technology to enrich children’s development and provide emotional support. BubblePal excels in multi-character interactions and multilingual communication, setting a new standard […]
Category Archives: Pr Newswire
Pr Newswire
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
10
Aug
Aug
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) — The Multidisciplinary Association for Psychedelic Studies (MAPS) is evaluating the path forward for safe, legal access to MDMA-assisted therapy following the announcement from Lykos Therapeutics that the potential approval […]
CHANGZHOU, China, Aug. 10, 2024 /PRNewswire/ — “Voltage and current outputs of the generator vehicle are normal, ensuring steady power supply to the low-voltage district!” On August 8, in the Liyang High-Tech Industrial Park, State Grid Changzhou Power Supply Company successfully utilized its innovatively developed low-voltage diesel generator vehicle for seamless grid integration, ensuring continuous […]
Smart Binhai, Glorious Competition! SINGAPORE, Aug. 10, 2024 /PRNewswire/ — With the success of the Hong Kong SAR Final Round of the 2024 China Tianjin Binhai New Area Talent Innovation and Entrepreneurship Competition (Overseas Competition) on 17th July, the Finals of the Singapore Division is about to kick off on 15th August. As the gateway to […]
A grand celebration of insurance knowledge and honor, united in wisdom and glory. KUALA LUMPUR, Malaysia, Aug. 10, 2024 /PRNewswire/ — The 15th Worldwide Chinese Life Insurance Congress & 2024 IDA Annual Conference is being held at the Malaysia International Trade and Exhibition Centre (MITEC) from August 9 to 12, 2024. This year’s theme, “CHANGE […]
Pr Newswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
10
Aug
Aug
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request […]
Pr Newswire
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
10
Aug
Aug
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100. Supportive data from preclinical study in atherosclerosis, a common obesity-related metabolic complication, is expected to be available H2-2024. […]
10
Aug
Aug
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today […]
10
Aug
Aug
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to four new employees. Fulcrum granted stock options to purchase shares of the […]
10
Aug
Aug
Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase 1b & 2/3 (“DRAGON II”) trial of Tinlarebant in adolescent STGD1 patients has been initiated and have completed enrollment for Phase 1b with six […]